Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis
Shuquan Wei, Kangwei Wang, Xiaomei Huang, et al.
International Journal of Immunopathology and Pharmacology (2019) Vol. 33
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Hirohito Yamaguchi, Jung-Mao Hsu, Wenhao Yang, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 5, pp. 287-305
Closed Access | Times Cited: 334
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
Wenxiao Jiang, Shuya Pan, Xin Chen, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 121
The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers
Ilaria Cavallari, Francesco Ciccarese, Evgeniya Sharova, et al.
Cancers (2021) Vol. 13, Iss. 23, pp. 5874-5874
Open Access | Times Cited: 118
MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting
Asif Ahmad Bhat, Obaid Afzal, Muhammad Afzal, et al.
Pathology - Research and Practice (2023) Vol. 253, pp. 154991-154991
Closed Access | Times Cited: 60
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Arefeh Zabeti Touchaei, Sogand Vahidi
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 34
The role of a ceRNA regulatory network based on lncRNA MALAT1 site in cancer progression
Kai Su, Nannan Wang, Qianqian Shao, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 137, pp. 111389-111389
Open Access | Times Cited: 103
Basis of PD1/PD-L1 Therapies
Barbara Seliger
Journal of Clinical Medicine (2019) Vol. 8, Iss. 12, pp. 2168-2168
Open Access | Times Cited: 102
Exosomal Long Non-Coding RNAs in Lung Diseases
Christophe Poulet, Makon‐Sébastien Njock, Catherine Moermans, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 10, pp. 3580-3580
Open Access | Times Cited: 95
Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment
Ya Luo, Jiqiao Yang, Jing Yu, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 72
MiRNAs and LncRNAs: Dual Roles in TGF-β Signaling-Regulated Metastasis in Lung Cancer
Xingning Lai, Jun Li, Libo Tang, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 4, pp. 1193-1193
Open Access | Times Cited: 71
Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review
Zaigang Zhou, Haoxiang Wang, Jie Li, et al.
International Journal of Biological Macromolecules (2023) Vol. 254, pp. 127911-127911
Closed Access | Times Cited: 28
Targeting long non-coding RNA MALAT1 reverses cancerous phenotypes of breast cancer cells through microRNA-561-3p/TOP2A axis
Sara Hajibabaei, Nahid Nafissi, Yasamin Azimi, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 25
Long noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance
Dexin Xu, Wenhai Wang, Duo Wang, et al.
Non-coding RNA Research (2024) Vol. 9, Iss. 2, pp. 388-406
Open Access | Times Cited: 12
Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy
Lokesh Kadian, Deepika Verma, Neelam Lohani, et al.
Molecular and Cellular Biochemistry (2024) Vol. 479, Iss. 12, pp. 3229-3254
Closed Access | Times Cited: 9
Deciphering the Interplay of the PD‐L1/MALT1/miR‐200a Axis During Lung Cancer Development
Sherien M. El‐Daly, Sahar S. Abdelrahman, Mona A. El‐Bana, et al.
Biotechnology and Applied Biochemistry (2025)
Closed Access | Times Cited: 1
Noncoding RNAs as potential mediators of resistance to cancer immunotherapy
Radhakrishnan Vishnubalaji, Hibah Shaath, Ramesh Elango, et al.
Seminars in Cancer Biology (2019) Vol. 65, pp. 65-79
Closed Access | Times Cited: 73
PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs
Milad Ashrafizadeh, Ali Zarrabi, Kiavash Hushmandi, et al.
Life Sciences (2020) Vol. 256, pp. 117899-117899
Closed Access | Times Cited: 65
<p>Regulatory Networks of LncRNA MALAT-1 in Cancer</p>
Shijian Fu, Yanhong Wang, Hang Li, et al.
Cancer Management and Research (2020) Vol. Volume 12, pp. 10181-10198
Open Access | Times Cited: 56
Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential
Ya-Nan Pi, Wen-Cai Qi, Bairong Xia, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 52
Exosomal long non-coding RNA LINC00662 promotes non-small cell lung cancer progression by miR-320d/E2F1 axis
Xin Lv, Yingjie Lian, Zhanye Liu, et al.
Aging (2021) Vol. 13, Iss. 4, pp. 6010-6024
Open Access | Times Cited: 42
LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer
Zhengwei Song, Xiaoguang Wang, Fei Chen, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 34
Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics
Hyein Jo, Kyeonghee Shim, Dooil Jeoung
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 5881-5881
Open Access | Times Cited: 31
The role of LncRNAs in tumor immunotherapy
Xuan Pan, Chenchen Li, Jifeng Feng
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 22
Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Ishita Gupta, Ola Hussein, Konduru S. Sastry, et al.
Advances in Cancer Biology - Metastasis (2023) Vol. 8, pp. 100107-100107
Open Access | Times Cited: 19
Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination
Zhijia Sun, Haixing Mai, Chunyuan Xue, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 12, pp. e007415-e007415
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top